1-1 of 1
Aojun Li
Close
Sort by
Journal Articles

CRC-403: A Phase 1/2 Study of bbT369, a Dual CD79a and CD20 Targeting CAR T Cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Frederick L. Locke, David B. Miklos, Michael Tees, Tina Bees, Aojun Li, Anna Truppel-Hartmann, Ian W. Flinn
Journal: Blood
Blood (2022) 140 (Supplement 1): 12716–12717.
https://doi.org/10.1182/blood-2022-162604
Published: 2022